FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282973621> ?p ?o ?g. }

• W4282973621 endingPage "704" @default.
• W4282973621 startingPage "704" @default.
• W4282973621 abstract "Abstract Background: Recapitulation of the full spectrum of genomic changes driving patient tumors have resulted in increased use of patient-derived xenograft (PDX) models in studies of basic cancer biology and preclinical drug development. Given the translational potential of PDXs and limited availability of pediatric cancer models, we established a PDX program to expand the existing collection of pediatric PDXs in the community and enable pre- and post-clinical studies. Methods: PDX generation requests were integrated into clinical workflows to maximize identification of eligible patients for informed consent and tissue collection at Memorial Sloan Kettering Cancer Center. Methodologies for tissue procurement and cryopreservation were optimized to facilitate implantation into host immunodeficient mice and enable multi-institutional tissue exchange for model building. A bioinformatics pipeline was established to allow molecular validation of engrafted PDXs using a next-generation targeted gene panel (MSK-IMPACT) evaluating concordance based on acquired mutations, copy number alterations and clonal structure. Results: Between November 2016 - October 2021, 379 PDX models were developed (265 distinct models) representing 69 discrete diagnoses. Sarcoma represents the most common model type (50 discrete osteosarcoma, 20 desmoplastic small round cell tumor, 14 Ewing sarcoma, 24 rhabdomyosarcoma, 2 CIC/DUX4 and 2 BCOR-rearranged sarcoma) followed by neuroblastoma (n=35), leukemia (n=44), and Wilms tumor (n=15). While the majority of PDXs were established from recurrent or metastatic tissue, 7 paired diagnostic/pre-therapy and post-therapy or relapse models were generated. Genomic characterization of PDXs demonstrate excellent concordance and recapitulation of single nucleotide variants (90%), structural (88%) and copy number variants (94%) between patient tumor and matched PDX. Discrepancies between matched patient/PDX pairs are due to sub-clonal heterogeneity in source tumors with clonal outgrowth in the PDX. Analysis of serial PDX passages also demonstrate stable recapitulation of the genomic profile. Establishment of a diverse PDX collection allowed preclinical evaluation of 10 targeted agents across a spectrum of pediatric tumors and provided the preclinical rationale for 3 investigator-initiated pediatric clinical trials. Conclusions: Investment in the development of a phenotypically diverse and biologically faithful collection of pediatric PDX models enables the goals of precision medicine. Optimization of PDX workflows and methods has also enabled the development of a pediatric PDX consortium (PROXC - Pediatric Research in Oncology Xenografting Consortium) to further support the development of pre- and post-clinical studies for pediatric cancer. Citation Format: Filemon S. Dela Cruz, Joseph G. McCarter, Daoqi You, Nancy Bouvier, Xinyi Wang, Kristina C. Guillan, Armaan H. Siddiquee, Katie B. Souto, Hongyan Li, Teng Gao, Dominik Glodzik, Daniel Diolaiti, Neerav N. Shukla, Joachim Silber, Umeshkumar K. Bhanot, Faruk Erdem Kombak, Diego F. Coutinho, Shanita Li, Juan E. Arango Ossa, Juan S. Medina-Martinez, Michael V. Ortiz, Emily K. Slotkin, Michael D. Kinnaman, Sameer F. Sait, Tara J. O'Donohue, Marissa Mattar, Maximiliano Meneses, Michael P. LaQuaglia, Todd E. Heaton, Justin T. Gerstle, Nicola Fabbri, Chelsey M. Burke, Irene M. Rodriquez-Sanchez, Christine A. Iacobuzio-Donahue, Julia L. Glade Bender, Ryan D. Roberts, Jason T. Yustein, Nino C. Rainusso, Brian D. Crompton, Elizabeth Stewart, Alejandro Sweet-Cordero, Leanne C. Sayles, Andrika D. Thomas, Michael H. Roehrl, Elisa de Stanchina, Elli Papaemmanuil, Andrew L. Kung. Development of a patient-derived xenograft (PDX) modeling program to enable pediatric precision medicine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 704." @default.
• W4282973621 created "2022-06-17" @default.
• W4282973621 creator A5001610703 @default.
• W4282973621 creator A5002001005 @default.
• W4282973621 creator A5002140630 @default.
• W4282973621 creator A5002327806 @default.
• W4282973621 creator A5003996137 @default.
• W4282973621 creator A5004111432 @default.
• W4282973621 creator A5006870182 @default.
• W4282973621 creator A5009386535 @default.
• W4282973621 creator A5009997118 @default.
• W4282973621 creator A5010909964 @default.
• W4282973621 creator A5012135963 @default.
• W4282973621 creator A5014830880 @default.
• W4282973621 creator A5019291158 @default.
• W4282973621 creator A5026257550 @default.
• W4282973621 creator A5027526459 @default.
• W4282973621 creator A5028367199 @default.
• W4282973621 creator A5028453851 @default.
• W4282973621 creator A5030467529 @default.
• W4282973621 creator A5030800597 @default.
• W4282973621 creator A5031759181 @default.
• W4282973621 creator A5037534727 @default.
• W4282973621 creator A5040223652 @default.
• W4282973621 creator A5040331260 @default.
• W4282973621 creator A5040523461 @default.
• W4282973621 creator A5042733900 @default.
• W4282973621 creator A5043757838 @default.
• W4282973621 creator A5045703343 @default.
• W4282973621 creator A5046103284 @default.
• W4282973621 creator A5046655874 @default.
• W4282973621 creator A5049274122 @default.
• W4282973621 creator A5051582267 @default.
• W4282973621 creator A5053843638 @default.
• W4282973621 creator A5056872209 @default.
• W4282973621 creator A5062090005 @default.
• W4282973621 creator A5062320984 @default.
• W4282973621 creator A5062561302 @default.
• W4282973621 creator A5066312999 @default.
• W4282973621 creator A5067084667 @default.
• W4282973621 creator A5069522876 @default.
• W4282973621 creator A5074844653 @default.
• W4282973621 creator A5076588912 @default.
• W4282973621 creator A5078901775 @default.
• W4282973621 creator A5083681305 @default.
• W4282973621 creator A5085354255 @default.
• W4282973621 creator A5086445887 @default.
• W4282973621 creator A5088238463 @default.
• W4282973621 creator A5090089940 @default.
• W4282973621 date "2022-06-15" @default.
• W4282973621 modified "2023-10-10" @default.
• W4282973621 title "Abstract 704: Development of a patient-derived xenograft (PDX) modeling program to enable pediatric precision medicine" @default.
• W4282973621 doi "https://doi.org/10.1158/1538-7445.am2022-704" @default.
• W4282973621 hasPublicationYear "2022" @default.
• W4282973621 type Work @default.
• W4282973621 citedByCount "0" @default.
• W4282973621 crossrefType "journal-article" @default.
• W4282973621 hasAuthorship W4282973621A5001610703 @default.
• W4282973621 hasAuthorship W4282973621A5002001005 @default.
• W4282973621 hasAuthorship W4282973621A5002140630 @default.
• W4282973621 hasAuthorship W4282973621A5002327806 @default.
• W4282973621 hasAuthorship W4282973621A5003996137 @default.
• W4282973621 hasAuthorship W4282973621A5004111432 @default.
• W4282973621 hasAuthorship W4282973621A5006870182 @default.
• W4282973621 hasAuthorship W4282973621A5009386535 @default.
• W4282973621 hasAuthorship W4282973621A5009997118 @default.
• W4282973621 hasAuthorship W4282973621A5010909964 @default.
• W4282973621 hasAuthorship W4282973621A5012135963 @default.
• W4282973621 hasAuthorship W4282973621A5014830880 @default.
• W4282973621 hasAuthorship W4282973621A5019291158 @default.
• W4282973621 hasAuthorship W4282973621A5026257550 @default.
• W4282973621 hasAuthorship W4282973621A5027526459 @default.
• W4282973621 hasAuthorship W4282973621A5028367199 @default.
• W4282973621 hasAuthorship W4282973621A5028453851 @default.
• W4282973621 hasAuthorship W4282973621A5030467529 @default.
• W4282973621 hasAuthorship W4282973621A5030800597 @default.
• W4282973621 hasAuthorship W4282973621A5031759181 @default.
• W4282973621 hasAuthorship W4282973621A5037534727 @default.
• W4282973621 hasAuthorship W4282973621A5040223652 @default.
• W4282973621 hasAuthorship W4282973621A5040331260 @default.
• W4282973621 hasAuthorship W4282973621A5040523461 @default.
• W4282973621 hasAuthorship W4282973621A5042733900 @default.
• W4282973621 hasAuthorship W4282973621A5043757838 @default.
• W4282973621 hasAuthorship W4282973621A5045703343 @default.
• W4282973621 hasAuthorship W4282973621A5046103284 @default.
• W4282973621 hasAuthorship W4282973621A5046655874 @default.
• W4282973621 hasAuthorship W4282973621A5049274122 @default.
• W4282973621 hasAuthorship W4282973621A5051582267 @default.
• W4282973621 hasAuthorship W4282973621A5053843638 @default.
• W4282973621 hasAuthorship W4282973621A5056872209 @default.
• W4282973621 hasAuthorship W4282973621A5062090005 @default.
• W4282973621 hasAuthorship W4282973621A5062320984 @default.
• W4282973621 hasAuthorship W4282973621A5062561302 @default.
• W4282973621 hasAuthorship W4282973621A5066312999 @default.
• W4282973621 hasAuthorship W4282973621A5067084667 @default.
• W4282973621 hasAuthorship W4282973621A5069522876 @default.
• W4282973621 hasAuthorship W4282973621A5074844653 @default.
• W4282973621 hasAuthorship W4282973621A5076588912 @default.

• next